The DNA damage response activates several pathways that stall the cell cycle and allow DNA repair. These consist of the well characterised ATR/CHK1 and ATM/CHK2 pathways in addition to a newly identified ATM/ATR/p38MAPK/MK2 checkpoint. Crucial to maintaining the integrity of the genome is the S-phase checkpoint that functions to prevent DNA replication until damaged DNA is repaired. Inappropriate expression of the protooncogene c-Myc is known to cause DNA damage. One mechanism by which c-Myc induces DNA damage is through binding directly to components of the pre-replicative complex thereby promoting DNA synthesis, resulting in replication-associated DNA damage and checkpoint activation due to inappropriate origin firing.
INTRODUCTION
The protein encoded by the proto-oncogene c-Myc (hereafter referred to as Myc) functions as an essential regulator of G 1 -S transition by promoting the transcription of mRNAs encoding proteins that drive cell cycle progression and cell growth (1) . Myc is tightly regulated at multiple levels and its de-regulated expression is associated with a wide range of cancers, particularly those of B-cell origin (2) . Further to these well established functions, Myc also has a role in DNA replication which is distinct from its transcriptional activity. It has been shown that Myc directly interacts with components of the pre-replicative complex and localises to early sites of DNA synthesis. Over-expression of Myc in this context results in checkpoint activation and DNA damage due to replication stress imposed by inappropriate replication origin activity (3) . Furthermore over-expression of Myc following DNA damage prevents cell-cycle arrest and promotes apoptosis (4) .
The DNA damage response (DDR) has traditionally been divided into two distinct yet parallel pathways, which utilise the upstream kinases ATR and ATM (5) . These signal to the checkpoint kinases, CHK1 or CHK2 respectively (6, 7) . Recently a third pathway has emerged that involves ATM/ATR signalling to p38 MAPK which in turn activates the newly identified checkpoint kinase MAPKAPK2 (MK2) (8, 9) . Both ATM/ATR and p38 MAPK activate p53 which transcriptionally regulates gene expression following DNA damage resulting in cell cycle arrest and/or apoptosis (10) (11) (12) . However, the DDR is not solely dependent upon p53, since p53-deficient cells can still respond to and repair DNA damage. In the absence of p53 the p38 MAPK pathway is essential for survival in response to chemotherapeutic drugs that cause DNA damage (13) , due to loss of MK2-mediated S-phase and/or G2/M arrest.
A newly identified component of the cellular response to DNA damage is the induction of microRNAs (miRNAs) which have apoptotic or cell-cycle arrest promoting activities. MiRNAs are non-coding RNAs, 21-25 nucleotides in length, that posttranscriptionally regulate gene expression by binding with imperfect complementarity to the 3′ UTR of target mRNAs and inhibiting their translation (14) . In particular p53
transcriptionally activates the miR-34 family of miRNAs and these appear to be vital components of the DDR (15) (16) (17) (18) (19) (20) . In vertebrates this family comprises miR-34a, synthesised as part of a large 30 kb transcript, and miR-34b and miR-34c which are expressed on a separate transcript and are subject to co-ordinated regulation (18) . These microRNAs are upregulated in response to DNA damage and have roles in regulating apoptosis and/or cell cycle arrest. This family is represented as a single orthologue in invertebrates and its role in the DNA damage response appears to be conserved, since C.elegans strains with mutations in the miR-34 gene are significantly more radio-sensitive than their wild-type counterparts (21).
Here we show that Myc is translationally repressed in response to DNA damage by the induction of miR-34c. Although miR-34c induction is maximal in p53-proficient cells, miR-34c induction and subsequent Myc repression also occur in cells that are devoid of p53, albeit to a lesser extent. In p53-deficient cells an alternative pathway mediates miR-34c induction which involves p38 MAPK signalling to MK2. Functionally, miR-34c-mediated repression of Myc following DNA damage is required to inhibit DNA synthesis and block cells in S-phase to prevent replication of damaged DNA. In the absence of this miRNAmediated repression, there is a Myc-dependent increase in checkpoint activation and DNA damage over and above that induced by etoposide alone. These findings suggest that following DNA damage miR-34c functions to repress Myc to prevent inappropriate replication.
RESULTS

miR-34c represses Myc following DNA damage
We have previously shown that Myc is repressed by miR-34c in HeLa cells via a target-site within its 3′ UTR (22) . Inhibition of miR-34c with a 2′ O-methyl oligonucleotide (anti-miR) relieves repression of a luciferase reporter harbouring the wild-type c-myc 3′ UTR (pLSVM3′) relative to a version with a point mutation in the miR-34c target-site (pLSVM3′mut) ( Figure 1A ). Anti-miRs directed against miR-34a or miR-34b did not have a significant effect on the wild-type c-myc 3′ UTR reporter ( Figure S1A ). To confirm that miR34c is the miRNA that is responsible for Myc repression, the 3′ UTR luciferase reporters were transfected into cells that have low miR-34c expression but high levels of miR-34a (HEK293 cells, Figure S2 ) along with a mimic corresponding to mature miR-34c or a control sequence. Transfection of miR-34c mimic led to repression of luciferase activity from the construct containing the wild-type c-myc 3′ UTR (pLSVM3′) relative to the mutant version (pLSVM3mut) ( Figure 1B ). Over-expression of miR-34a or miR-34b led to repression of luciferase activity from the wild-type c-myc 3′ UTR construct but this failed to reach significance ( Figure S1B ). These data demonstrate that miR-34 represses Myc predominantly through miR-34c with a more minor role for miR-34a and miR-34b.
To determine whether miR-34c represses Myc following DNA damage, HEK293 cells, which express low basal levels of miR-34c ( Figure S2B ), were treated with etoposide to introduce both single and double strand breaks into DNA. Treatment with etoposide resulted in increased p53, p21 and miR-34c expression as expected and a decrease in Myc protein levels with no decrease in c-myc mRNA levels, measured by western and northern analysis respectively ( Figure 1C ). Pulse-chase immuno-precipitation experiments showed no difference in Myc protein half-life upon etoposide treatment ( Figure S1C ) demonstrating that Myc is repressed at the translational level following DNA damage. To determine whether the c-myc 3′ UTR was responsible for Myc repression following DNA damage, HEK293 cells were transfected with the luciferase reporter constructs and treated with etoposide. Exposure of cells to etoposide resulted in a 50% decrease in luciferase activity from the reporter containing the wild-type c-myc 3′ UTR relative to the mutant version ( Figure 1D ). Inhibition of miR-34c with a specific anti-miR relieved repression of this reporter construct when cells were exposed to etoposide. Furthermore, DNA damage induced repression of endogenous Myc was relieved by more than 40% following miR-34c inhibition ( Figure 1E ). These data show that miR-34c represses Myc translation following DNA damage via a highly conserved target-site within its 3′ UTR.
Repression of Myc by miR-34c following DNA damage in p53-deficient cells
Initial qPCR analysis for miR-34 expression in different cell-lines revealed that whilst the basal expression levels of miR-34a correlated with p53 status levels of miR-34c did not ( Figure S2A and B). In fact miR-34c expression was highest in two p53 negative cell-lines, SaOS2 and p53 -/-mouse embryonic fibroblasts ( Figure S2B ). This prompted us to investigate whether miR-34c induction could occur in the absence of p53. Three different p53 negative cell lines were treated with etoposide, all of which showed ~2-fold or greater increase in miR-34c expression following DNA damage (Figure 2A and S2C ). Enforced expression of p53 in SaOS2 cells demonstrated that miR-34 induction was enhanced by p53, consistent with previous reports ( Figure S3A ) (16, 17) . Depletion of p53 by siRNA in HEK293 cells reduced miR-34c induction by half ( Figure S3C ). However expression of p53 in H1299 (also p53-negative) cells, by use of a tetracycline inducible form of wild-type p53, had no effect on miR-34c induction ( Figure S3B ). These data demonstrate that whilst p53 is clearly an important regulator, other factors influence miR-34c expression in its absence. We next sought to determine whether the ~2-fold induction of miR-34c observed in p53-deficient cells was sufficient to repress Myc. To this end p53 -/-MEFs were transfected with a control anti-miR or anti-miR-34c and treated with etoposide. We observed miR-34c-dependent Myc repression in response to DNA damage ( Figure 2B ) thus 2-fold induction of miR-34c is sufficient to repress Myc ( Figure 2 ). These data demonstrate that whilst p53 is an important factor for miR-34c regulation in response to DNA damage, in its absence, other pathways can induce expression of miR-34c to maintain Myc repression.
MiR-34 is induced by p38 MAPK/MK2 signalling following DNA damage
The DNA damage response involves a cascade of signalling events, mediated by Serine/Threonine protein kinases, which act on their substrates to enforce the biological output of the DDR. The involvement of these pathways in the regulation of microRNAs, specifically the induction of miR-34, have not been investigated. One of the earliest events in the DNA damage response is the recognition of DNA breaks by one or more of the sensor kinases ATM, ATR or DNA-PK. These proteins are all members of the highly conserved phosphotidyl-inositol-3-kinase-like (PI3K) family, and as such are inhibited by LY294002, a PI3K inhibitor. To determine the effect of ATM/ATR/DNA-PK inhibition on miR-34c induction HEK293 cells were treated with LY294002 for 30 mins prior to etoposide treatment and miR-34 levels measured by qPCR. In the absence of LY294002 miR-34c was induced 14-fold and miR-34a was induced 5-fold ( Figure 3A ). However, when cells were pre-treated with LY294002 miR-34a and miR-34c induction was prevented ( Figure 3A ).
These data are consistent with the idea that sites of DNA damage are detected by ATM, ATR or DNA-PK which in turn activate a pathway that leads to miR-34c induction. Analysis of Myc levels by western blot demonstrated that this reduction in miR-34c levels following DNA damage was sufficient to prevent Myc repression ( Figure 3A ). Western analysis confirmed that phosphorylation of ATM/ATR substrates p38 MAPK, CHK1 and CHK2 was reduced following treatment with LY294002 ( Figure 3A) . The p38 MAPK/MK2 pathway is an important regulator of the DNA damage response in both p53-proficient and p53-deficient cells but in the absence of p53 it becomes essential (13) . We hypothesised that miR-34c induction may occur through this signalling pathway. To test this HEK293 cells were pretreated with SB203580, a p38 MAPK inhibitor, or PD098059, a MEK1/2 inhibitor as a control, for 30 mins prior to etoposide treatment. Inhibition of p38 MAPK but not MEK1/2 prevented etoposide-induced miR-34c expression and repression of Myc ( Figure 3B ).
Western blotting for phosphorylated MK2, a direct p38 MAPK substrate, confirmed inhibition of p38 kinase activity ( Figure 3B ). These data show that p38 MAPK inhibition prevents miR-34c induction in response to DNA damage. However, this could be due to disruption of signalling to p53 despite continued p21 induction under these conditions ( Figure   3B ). To directly assess whether MK2 could influence miR-34c expression, HEK293 cells were transfected with an siRNA targeting MK2 or expression vectors containing wild-type MK2 (MK2 Wt), a mutant version that is catalytically inactive (MK2 K76R), or a constitutively active version (MK2 EE) (23, 24) . Depletion of MK2 by siRNA significantly inhibited miR-34c induction ( Figure 3C ), however, this inhibition was not sufficient to prevent Myc repression ( Figure S4A ) perhaps due to incomplete depletion of MK2, a role for another p38 substrate, or continued signalling to p53 under these conditions. Over-expression of wild-type MK2 or a constitutively active form of MK2 enhanced miR-34c induction following etoposide treatment whilst a version of MK2 with a mutation in the catalytic domain had no effect ( Figure 3C ). The finding that MK2 can influence miR-34c expression prompted us to ascertain whether MK2 could induce miR-34c independently of p53 in a p53-deficient background. To this end p53 -/-MEFs were transfected with empty vector or constitutively active MK2 (MK2 EE) and treated with SB203580 prior to etoposide treatment. Pre-treatment of these cells with SB203580 ( Figure 3D ) or transfection with an siRNA targeting MK2 ( Figure S4B ) prevented miR-34c induction in response to etoposide which could be overcome by addition of MK2EE ( Figure 3D ). This demonstrates that MK2 functions downstream of p38 MAPK in this pathway ( Figure S4C ). These data show that the p38 MAPK influences miR-34c induction via MK2 in both p53-proficient and p53-deficient cells. However, MK2 is only completely required for this induction in cells that lack functional p53 (Figure 3D and S4C) .
miR-34c repression of Myc mediates S-phase arrest and inhibition of DNA synthesis following DNA damage.
MK2 is an important regulator of the cell cycle following DNA damage mediating both S-phase and G2/M arrest. We hypothesised that miR-34c repression of Myc may play a role in regulating the cell cycle following DNA damage. EdU (5-ethynyl-2´-deoxyuridine) is a thymidine analog that is incorporated into DNA during active DNA synthesis in S-phase (25) . Cells that are arrested in S-phase due to exposure to ionizing radiation or radio-mimetic drugs do not incorporate EdU. However, cells with defects in S-phase checkpoints can continue to incorporate EdU following exposure to such agents, a process known as radioresistant DNA synthesis (26) .
To examine the effect of miR-34c repression of Myc on the cell cycle HEK293 cells were transfected with combinations of anti-miR-34c and c-myc siRNA. Cells were transfected as indicated and 24 hours later were treated with etoposide. One hour prior to harvest cells were pulse labelled with EdU then fixed and stained with propidium iodide as a measure of DNA content. When control cells were treated with etoposide there was arrest in S and G2/M phases of the cell cycle (Figure 4Ai and S5Ai) and a decrease in DNA synthesis measured by EdU incorporation ( Figure 4B , first column and S5Ai). However, inhibition of miR-34c with an anti-miR prevented S-phase arrest, lead to increased DNA synthesis and a subsequent G2/M arrest (Figure 4Aii and 4B, second column and S5Aiii). Importantly when miR-34c was inhibited and Myc levels were reduced using siRNA this phenotype was reversed (Figure 4Aiii and B, third column and S5Aiv). The block observed in S-phase in the presence of miR-34c must therefore result from a lack of Myc expression alone. Western blot analysis confirmed a relief of Myc repression and subsequent knockdown in etoposide treated cells ( Figure 4C ). These data demonstrate that Myc repression is required for cells to arrest in S-phase following DNA damage, and that a major physiological target of miR-34c is Myc.
It is known that over-expression of Myc can result in DNA damage due to inappropriate replication origin firing resulting in checkpoint activation (3). We therefore sought to determine the consequence of continued Myc expression following DNA damage by inhibiting miR-34c. When miR-34c was inhibited following DNA damage, by use of an anti-miR, there was a Myc-dependent increase in CHK2 ( Figure 4C ) phosphorylation, indicative of activation by ATM, and a Myc-dependent increase in H2AX phosphorylation, a marker of DNA damage, over and above that induced by etoposide alone ( Figure 4C ). These data show that continued expression of Myc following DNA damage causes inappropriate DNA replication ( Figure 4B ), thereby perpetuating the DDR in a feed-forward loop that miR34c functions to prevent.
DISCUSSION
The DNA damage response requires the concerted action of a number of distinct pathways including those that detect the damage, halt cell cycle progression and mediate DNA repair. The transcriptional pathways that regulate these processes are fairly well described (27) ; however, more recently it has become apparent that proteins involved in this response are also post-transcriptionally regulated. For example, it has been shown that following exposure to ionizing radiation or radio-mimetic drugs, miR-34 levels are upregulated, and expression of one of the members of this family, miR-34a, is required for p53-mediated apoptosis under certain conditions (15) (16) (17) (18) (19) (20) . Although some of the downstream targets of the miR-34 family have been determined, the biological effects mediated by specific targets are not fully understood. We and others have shown that Myc levels are controlled by miR-34 (22, 28) . Although it has been shown previously that levels of Myc are reduced following DNA damage by a number of different mechanisms, including changes in the rate of transcription and protein turnover (29) (30) (31) , the possible involvement of miRNAs has not been investigated. It was therefore timely to investigate the role of miR-34c in the control of Myc repression following DNA damage and its importance in this process.
Our data show that Myc is repressed by miR-34c following DNA damage via a highly conserved target-site within its 3′ UTR (Figure 1 ). Other members of the miR-34 family may repress Myc however their ability to exert repression via the 3′ UTR in reporter assays is limited ( Figure S1A and B) . Here we show that a major biological function of miR-34c following DNA damage is to repress Myc. This repression mediates S-phase arrest thus preventing DNA replication ( Figure 4A and B) , and it is probable that this is one mechanism by which MK2 performs its checkpoint function. When miR-34c repression of Myc is inhibited cells undergo enhanced DNA damage, in addition to that induced by etoposide alone (Figure 4C ), likely due to inappropriate Myc-dependent DNA replication. Taken together these data suggest that miR34c serves to remove Myc following DNA damage downstream of p38 MAPK/MK2 to prevent replication stress which may otherwise lead to genomic instability. Since miR-34c-mediated repression of Myc is downstream of p38 MAPK (Figure 3) , a general stress response kinase, this mechanism may prevent Myc-dependent replication stress in response to a diverse range of cellular stresses. It has recently been proposed that facilitating replication under stress conditions may be an oncogenic function of Myc (34) . Therefore epigenetic silencing of miR-34b/c, frequently observed in cancers (28) , could lead to aberrant Mycinduced replication and transformation.
Materials and Methods
Cell culture and drug treatments HEK293, SaOS2, p53 -/-MEFs and HeLa cells were grown under standard conditions. H1229 p53 inducible cells were grown as described previously (35, 36) . Cells were treated with etoposide, adriamycin (doxorubicin), or pre-treated for 30 min with SB203580 (25 μM), PD098059 (50 μM) or LY294002 (25 μM) (Sigma-Aldrich) as indicated.
Transient transfections and luciferase assays
DNA transfections were performed using the calcium phosphate method. RNA and DNA cotransfections were performed using Lipofectamine 2000 (Invitrogen). MicroRNA mimic and 2′ O-methyl-oligonucleotide transfections were performed using Lipofectamine RNAiMax (Invitrogen). Luciferase assays were preformed as described previously (22) .
Plasmids, siRNAs, microRNA mimics and 2′O-methyl oligonucleotides pRLSVM3′, pRLSVM3′mut have been described previously (22) . pcDNA-MK2Wt-Myc, pcDNA-MK2K76R and pcDNA-MK2EE were a kind gift from Mathias Gaestel. siRNAs to p53 (20 nM final concentration) and c-Myc (20 nM) were purchased as smart-pool ON-TARGET plus siRNAs from Dharmacon. For oligonucloetide sequences see Supplementary materials and methods.
Antibodies, western blots and c-Myc immuno-precipitation
Proteins were blotted using the following primary antibodies: c-Myc: 9E10 antibody (SigmaAldrich), p53: D01 antibody (Santa-Cruz Biotechnology), p21/Waf1/Cip: DCS60, PARP, phospho-MK2: 27B7, phospho-p38: 12F8, phospho-Chk1: Ser 296, phospho-Chk2: Thr 68, phospho-Histone H2A.X: Ser 139 (all Cell Signaling Technology) and beta-actin was detected using AC15 (Sigma-Aldrich). For details of c-Myc immuno-precipitation see Supplementary materials and methods.
MicroRNA northern blots
Total RNA was extracted from cells using Tri-reagent (Sigma-Aldrich) according to the manufacturer's instructions, except that an equal volume of isopropanol was used for the precipitation step. For full details of microRNA northern see Supplementary materials and methods.
Northern Blots
Were performed as described previously (22) .
Quantitative PCR for microRNA 100ng of total RNA was reverse transcribed and amplified using the Taqman microRNA assay kit (Applied Biosystems) according to the manufacturer's instructions in a Stratagene Mx3005P cycler. Ct values were calculated and data expressed as 2-ΔCt′ (37).
Cell cycle analysis
Cells were treated as indicated, 60 min prior to harvest were labeled with 20 μM EdU, harvested and processed using the Click-iT EdU Alexa Fluor 488 Flow Cytometry assay kit (Invitrogen) and stained for DNA content with 25 μg/mL propidium iodide (Sigma-Aldrich).
Samples were subject to cell cycle analysis on a BD FACSAria special order system. Data were analysed using the WIN-MDI and Cylchred software. 
